You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 7,741,536


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 7,741,536
Title:Expression of human serum albumin in plastids
Abstract: Humans Serum Albumin (HSA) or an HSA fusion protein is expressed in plant plastids. A plastid transformation vector is made which contains an expression cassette that contains regulatory sequences, the coding region for HSA or an HSA fusion protein and a selectable marker coding sequence. The vector is used to transform a plant where the plant expresses the HSA or HSA fusion protein. HSA is isolated and purified from the plant. A preferred plant is tobacco.
Inventor(s): Daniell; Henry (Winter Park, FL)
Assignee: University of Central Florida Research Foundation, Inc. (Orlando, FL)
Application Number:11/406,522
Patent Claims:1. A stable plastid transformation and expression vector competent for stably transforming a target plastid genome, wherein said vector comprises an expression cassette comprising as operably linked components, in the 5' to the 3' direction of translation, a promoter operative in a plastid, a selectable marker sequence, a heterologous DNA sequence coding for Human Serum Albumin or an Human Serum Albumin fusion protein, a transcription termination region functional in said plastid, and, flanking each side of the expression cassette, flanking DNA sequences which are homologous to a DNA sequence comprising a transcriptionally active spacer sequence of the target plastid genome, whereby stable integration of the heterologous DNA sequence into the target plastid genome is facilitated through homologous recombination of the flanking DNA sequences with the homologous sequences in the target plastid genome.

2. The vector of claim 1, wherein the heterologous DNA sequence codes for human serum albumin.

3. The vector of claim 1, wherein said spacer sequence is conserved in plastid genomes of different plant species, whereby stable intergration of the expression cassette into the target plastid genome is facilitated through homolgous recombination of the flanking sequences with the homologous sequences in the target plastid genome.

4. A stably transformed plant which comprises plastids stably transformed with the vector of claim 1.

5. The transformed plant of claim 4 which is a tobacco or alfalfa plant.

6. A stable plastid transformation and expression vector competent for stably transforming a target plastid genome, wherein said vector comprises an expression cassette comprising, as operably linked components, a heterologous DNA sequence coding for a human serum albumin protein or human serum albumin fusion protein, regulatory sequences to control the expression of said human serum albumin or human serum albumin fusion protein, and, flanking each side of the expression cassette, flanking DNA sequences which are homologous to a DNA sequence comprising a transcriptionally active spacer sequence of the target plastid genome, whereby stable integration of the heterologous DNA sequence and regulatory sequences into the plastid genome is facilitated through homologous recombination of the flanking DNA sequences with the homologous sequences-in the target plastid genome.

7. The stable vector of claim 6, wherein the regulatory sequences include a 5' UTR sequence positioned to enhance the translation of the protein.

8. A method of producing Human Serum Albumin, said method comprising: a. growing a plant that contains a transgenic plastid that comprises an expression cassette comprising a promoter operative in said plastid, a selectable marker sequence, a heterologous DNA sequence coding for Human Serum Albumin or an Human Serum Albumin fusion protein, and a transcription termination region functional in said plastid inserted into a transcriptionally active spacer sequence in the plastid genome of said transgenic plastid such that it expresses human serum albumin or the human serum albumin fusion protein in the plastid, b. harvesting the plant, and c. purifying the human serum albumin or human serum albumin fusion protein from said plant.

Details for Patent 7,741,536

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Grifols Therapeutics Llc ALBUKED, PLASBUMIN-20, PLASBUMIN-25, PLASBUMIN-5 albumin (human) For Injection 101138 10/21/1942 ⤷  Try a Trial 2017-08-07
Baxalta Us Inc. BUMINATE, FLEXBUMIN albumin (human) Injection 101452 03/03/1954 ⤷  Try a Trial 2017-08-07
Csl Behring Ag ALBURX albumin (human) Injection 102366 07/23/1976 ⤷  Try a Trial 2017-08-07
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.